Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025
Day One Biopharmaceuticals (DAWN) has announced it will host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to discuss its first quarter 2025 financial results and corporate updates. The live audio webcast will be available on the company's Investors & Media page, with a replay accessible for 30 days following the event in the Events & Presentations section.
Day One Biopharmaceuticals (DAWN) ha annunciato che terrà una conference call e una webcast il martedì 6 maggio 2025 alle 16:30 ET per discutere i risultati finanziari del primo trimestre 2025 e gli aggiornamenti aziendali. La trasmissione audio in diretta sarà disponibile nella pagina Investitori & Media dell'azienda, con una registrazione accessibile per 30 giorni dopo l'evento nella sezione Eventi & Presentazioni.
Day One Biopharmaceuticals (DAWN) ha anunciado que realizará una conferencia telefónica y una transmisión en vivo el martes 6 de mayo de 2025 a las 4:30 p.m. ET para discutir los resultados financieros del primer trimestre de 2025 y actualizaciones corporativas. La transmisión de audio en vivo estará disponible en la página de Inversores y Medios de la compañía, con una repetición accesible durante 30 días después del evento en la sección de Eventos y Presentaciones.
Day One Biopharmaceuticals (DAWN)는 2025년 5월 6일 화요일 오후 4시 30분(동부시간)에 2025년 1분기 재무 실적 및 회사 업데이트를 논의하기 위한 컨퍼런스 콜과 웹캐스트를 진행할 예정임을 발표했습니다. 라이브 오디오 웹캐스트는 회사의 투자자 및 미디어 페이지에서 시청할 수 있으며, 이벤트 후 30일간 이벤트 및 프레젠테이션 섹션에서 다시보기 가능합니다.
Day One Biopharmaceuticals (DAWN) a annoncé qu'elle tiendra une conférence téléphonique et une webdiffusion le mardi 6 mai 2025 à 16h30 ET pour discuter des résultats financiers du premier trimestre 2025 ainsi que des mises à jour de l'entreprise. La webdiffusion audio en direct sera disponible sur la page Investisseurs & Médias de la société, avec un replay accessible pendant 30 jours après l'événement dans la section Événements & Présentations.
Day One Biopharmaceuticals (DAWN) hat bekanntgegeben, dass am Dienstag, den 6. Mai 2025 um 16:30 Uhr ET eine Telefonkonferenz und ein Webcast stattfinden werden, um die Finanzergebnisse des ersten Quartals 2025 sowie Unternehmensupdates zu besprechen. Der Live-Audio-Webcast ist auf der Investor & Media-Seite des Unternehmens verfügbar, mit einer Wiedergabe, die 30 Tage nach der Veranstaltung im Bereich Veranstaltungen & Präsentationen abrufbar ist.
- None.
- None.
BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the first quarter 2025.
Live audio of the webcast will be accessible on the Day One Investors & Media page. An archived version of the webcast will be available for replay on the Events & Presentations section of the Day One Investors & Media page for 30 days following the event.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan, Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from day one.
Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments.
The Company’s pipeline includes tovorafenib (OJEMDA™), DAY301 and a VRK1 inhibitor program. Day One is based in Brisbane, California. For more information, please visit www.dayonebio.com or find the Company on LinkedIn or X.
Day One uses its Investor Relations website (ir.dayonebio.com), its X handle (x.com/DayOneBio), and LinkedIn Home Page (linkedin.com/company/dayonebio) as a means of disseminating or providing notification of, among other things, news or announcements regarding its business or financial performance, investor events, press releases, and earnings releases, and as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
DAY ONE MEDIA
Laura Cooper, Head of Communications
media@dayonebio.com
DAY ONE INVESTORS
LifeSci Advisors, PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
When will Day One Biopharmaceuticals (DAWN) report Q1 2025 earnings?
How can investors access DAWN's Q1 2025 earnings call?
How long will DAWN's Q1 2025 earnings call replay be available?
What will be discussed in Day One Biopharmaceuticals' Q1 2025 earnings call?
